A Phase 2 interventional study of Dupilumab and Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 42 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2020-05-07.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 17th largest by enrollment, is one of 4 that started in 2014, is one of 7 in phase 2, and was the 7th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 194 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 13th largest by enrollment of the 25 interventional ones that give a count, is one of 4 that started in 2014, is one of 8 in phase 2, and was the 8th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This was a 32-week, randomized, double-blind, placebo-controlled, parallel-group study assessing immunization responses to vaccination in adults with moderate to severe atopic dermatitis who are treated with subcutaneous dupilumab.
Key Inclusion Criteria:
Key Exclusion Criteria:
The information listed above is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial and not all inclusion/ exclusion criteria are listed.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection qw from Week 1 to Week 15.
Drug: Placebo
Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection qw from Week 1 to Week 15.
Drug: Dupilumab
Administered via subcutaneous injection.
Also known as: REGN668, SAR231893, Dupixent
An inactive substance containing no medicine administered via subcutaneous injection.
Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16
A positive response was defined as a ≥ 4-fold increase from pre-vaccination at baseline in anti-tetanus immunoglobulin G (IgG) titer for participants with a pre-vaccination tetanus antibody titers ≥ 0.1 IU/ml or a titer of ≥ 0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml. There was no planned statistical hypothesis testing regarding the difference in immune response between the 2 treatment groups for this study, therefore no formal statistical hypothesis between groups was performed.
Time frame: Week 16
Percentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16
Participants with positive response defined as a ≥2-fold increase from pre-vaccination baseline in anti-tetanus IgG titer for participants with pre-vaccination tetanus antibody titers ≥0.1 IU/ml or a titer of ≥0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml.
Time frame: Week 16
Percentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 16
A positive response to the Menomune vaccine was a serum bactericidal antibody (SBA) titer of ≥8 for serogroup C.
Time frame: Week 16
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 16 were counted as non-responders.
Time frame: Week 16
Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
Time frame: Week 16
Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment use were set to missing and participants with missing EASI score at Week 16 were considered as non-responders.
Time frame: Week 16
Change From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16
Pruritus NRS was an assessment tool that was used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Weekly average obtained in the 7-day period prior to the baseline visit. Values after first rescue medication use were set to missing and missing values were imputed by Last observation carried forward (LOCF).
Time frame: Baseline to Week 16
Change From Baseline in Body Surface Area (BSA) Affected by AD at Week 16
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Change From Baseline in Global Individual Signs Score (GISS) Components (Erythema, Infiltration/Papulation, Excoriations and Lichenification) at Week 16
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue treatment were set to missing. Analysis was completed using MMRM model which includes treatment, randomization strata, visit, baseline value, treatment-by-visit interaction, and baseline-by-visit interaction as covariates. These results are observed results without imputation.
Time frame: Baseline to Week 16
Changes From Baseline in GISS Cumulative Score to Week 16
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
Change in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16
The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
Time frame: Baseline to Week 16
The study was conducted at approximately 50 study sites in United States (US) between 05 August 2014 and 15 September 2015. A total of 243 participants were screened in the study.
| Milestone | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Started | 97 | 97 |
| Completed | 92 | 89 |
| Not completed | 5 | 8 |
| Withdrew: Adverse event | 0 | 5 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Other than specified above | 0 | 1 |
A positive response was defined as a ≥ 4-fold increase from pre-vaccination at baseline in anti-tetanus immunoglobulin G (IgG) titer for participants with a pre-vaccination tetanus antibody titers ≥ 0.1 IU/ml or a titer of ≥ 0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml. There was no planned statistical hypothesis testing regarding the difference in immune response between the 2 treatment groups for this study, therefore no formal statistical hypothesis between groups was performed.
| Percentage of participants | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants With a Positive Response (≥4-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16 | 83.7 | 83.3 |
Participants with positive response defined as a ≥2-fold increase from pre-vaccination baseline in anti-tetanus IgG titer for participants with pre-vaccination tetanus antibody titers ≥0.1 IU/ml or a titer of ≥0.2 IU/ml for participants with pre-vaccination titers of \<0.1 IU/ml.
| Percentage of participants | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants With a Positive Response (≥2-Fold Increase) to Tetanus Toxoid (the Adacel [Tdap] Vaccine) at Week 16 | 94.6 | 95.6 |
A positive response to the Menomune vaccine was a serum bactericidal antibody (SBA) titer of ≥8 for serogroup C.
| Percentage of participants | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants With a Positive Response (SBA Antibody Titer of ≥8 for Serogroup C) to Menomune Vaccine at Week 16 | 87.0 | 86.7 |
IGA was an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response was an IGA score of 0 (clear) or 1 (almost clear). Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 16 were counted as non-responders.
| Percentage of participants | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of "0" or "1" at Week 16 | 10.3 | 44.3 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-50 responders were the participants who achieved ≥50% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment were set to missing and participants with missing EASI score at Week 16 were counted as non-responders.
| Percentage of participants | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants Achieving an Eczema Area and Severity Index-50 (EASI-50) (≥50% Improvement From Baseline) at Week 16 | 32.0 | 72.2 |
The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. Values after first rescue treatment use were set to missing and participants with missing EASI score at Week 16 were considered as non-responders.
| Percentage of participants | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Percentage of Participants Achieving an Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16 | 19.6 | 53.6 |
Pruritus NRS was an assessment tool that was used to report the intensity of participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Weekly average obtained in the 7-day period prior to the baseline visit. Values after first rescue medication use were set to missing and missing values were imputed by Last observation carried forward (LOCF).
| Units on a scale | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Peak Weekly Averaged Pruritis Numerical Rating Scale (NRS) Scores at Week 16 | -2.11 ± 0.259 | -4.24 ± 0.250 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| Percentage of BSA | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Change From Baseline in Body Surface Area (BSA) Affected by AD at Week 16 | -11.0 ± 2.11 | -28.7 ± 2.00 |
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue treatment were set to missing. Analysis was completed using MMRM model which includes treatment, randomization strata, visit, baseline value, treatment-by-visit interaction, and baseline-by-visit interaction as covariates. These results are observed results without imputation.
| Units on a scale | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Erythema | -0.4 ± 0.08 | -0.9 ± 0.08 |
| Infiltration/Papulation | -0.4 ± 0.08 | -1.1 ± 0.08 |
| Excoriations | -0.5 ± 0.09 | -1.2 ± 0.08 |
| Lichenification | -0.4 ± 0.09 | -1.0 ± 0.09 |
Individual components of the AD lesions (erythema, infiltration/papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0 = none, 1 = mild, 2 = moderate and 3 = severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| Units on a scale | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Changes From Baseline in GISS Cumulative Score to Week 16 | -1.7 ± 0.28 | -4.1 ± 0.28 |
The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). Values after first rescue medication use were set to missing and missing values were imputed by LOCF.
| Units on a Scale | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Change in Patient Oriented Eczema Measure (POEM) Score From Baseline to Week 16 | -4.8 ± 0.72 | -13.1 ± 0.70 |
Collected over Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 32) regardless of seriousness or relationship to investigational product. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo qw | 0/97 (0%) | 0/97 (0%) | 29/97 (29.9%) |
| Dupilumab 300 mg qw | 0/97 (0%) | 3/97 (3.1%) | 30/97 (30.9%) |
| Event | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Serum sickness-like reactionImmune system disorders | 0/97 | 1/97 |
| Mycosis fungoides stage ivNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/97 | 1/97 |
| Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/97 | 1/97 |
| Event | Placebo qw | Dupilumab 300 mg qw |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 14/97 | 11/97 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 11/97 | 1/97 |
| ConjunctivitisInfections and infestations | 0/97 | 8/97 |
| Injection site reactionGeneral disorders | 0/97 | 5/97 |
| NasopharyngitisInfections and infestations | 5/97 | 4/97 |
| HeadacheNervous system disorders | 3/97 | 5/97 |
The safety analysis set (SAF) included all randomized participants who received any study drug, and was analyzed as treated. Any participant given at least 1 dupilumab injection was assigned to the dupilumab group. The safety analysis was based on the SAF.
| Age, Continuous(years) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 39.9 ± 14.04 | 39.2 ± 13.55 | 39.6 ± 13.77 |
| Sex: Female, Male(Participants) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Female | 51 | 48 | 99 |
| Male | 46 | 49 | 95 |
| Ethnicity (NIH/OMB)(Participants) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 15 | 28 |
| Not Hispanic or Latino | 84 | 81 | 165 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| White | 67 | 60 | 127 |
| Black or African American | 17 | 23 | 40 |
| Asian | 11 | 12 | 23 |
| American Indian or Alaska Native | 0 | 1 | 1 |
| Other | 2 | 1 | 3 |
| Anti-tetanus Immunoglobulin G (IgG) Titer(IU/mL) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 1.74 ± 1.908 | 1.51 ± 1.328 | 1.62 ± 1.644 |
| Eczema Area and Severity Index (EASI) Score(units on a scale) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 31.23 ± 13.771 | 29.04 ± 13.085 | 30.14 ± 13.442 |
| Investigator Global Assessment (IGA) Score(units on a scale) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 3.4 ± 0.49 | 3.4 ± 0.49 | 3.4 ± 0.49 |
| Weekly Peak Pruritus Numeric Rating Scale (NRS)(Units on a Scale) | Placebo qw | Dupilumab 300 mg qw | Total |
|---|---|---|---|
| Mean | 7.3 ± 2.19 | 7.4 ± 2.20 | 7.3 ± 2.19 |
2 further baseline measures are reported on the registry.
Ran from Aug 2014 to primary completion in Sep 2015, 13 months.
Results were first posted in May 2020, 4 years 7 months after primary completion. A results delay was requested in Feb 2017.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 13 months is close to that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab